-- 周二，加拿大皇家银行资本市场(RBC Capital Markets)在森科能源(Suncor Energy，股票代码：SU.TO)发布第一季度业绩后，维持了对该公司“跑赢大盘”的评级和100加元的目标价。 森科能源第一季度每股运营收益为1.93加元，低于RBC此前预测的2.01加元，但与华尔街预期相符。 调整后运营资金为每股3.39加元，高于RBC此前预测的3.32加元和华尔街预期的3.29加元。 森科能源报告称，其总日产量为87.5万桶，高于RBC此前预测的86万桶/日和华尔街预期的86.8万桶/日。 该公司第一季度资本支出为10.8亿加元，低于RBC和华尔街此前预测的12.2亿加元。 森科能源依然是加拿大皇家银行（RBC）最青睐的综合能源生产商，并入选RBC全球能源最佳投资标的名单。 截至周三多伦多证券交易所的最后交易日，森科能源的股价为每股89.57加元。
Price: $89.68, Change: $-5.37, Percent Change: -5.65%
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%